Zhitong Finance App News, Jianshi Technology-B (09877.HK) issued an announcement. Recently, the 6-month follow-up results of the LUX-Valve Plus transvascular tricuspid valve interventional replacement system (TRAVEL III) and the 2-year long-term follow-up results of the multi-center clinical trial (TRAVEL II) were released at the 2026 American Transcatheter Cardiovascular Academic Conference (TCT 2026), showing that the company's products have excellent performance in terms of safety, efficacy and durability, and are expected to meet a wide range of unmet expectations. clinical requirements.

Zhitong Finance App News, Jianshi Technology-B (09877.HK) issued an announcement. Recently, the 6-month follow-up results of the LUX-Valve Plus transvascular tricuspid valve interventional replacement system (TRAVEL III) and the 2-year long-term follow-up results of the multi-center clinical trial (TRAVEL II) were released at the 2026 American Transcatheter Cardiovascular Academic Conference (TCT 2026), showing that the company's products have excellent performance in terms of safety, efficacy and durability, and are expected to meet a wide range of unmet expectations. clinical requirements.